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ABSTRACT OF THESIS 
 
 
 
THE THIOL REDOX SYSTEM IN OXLDL-INDUCED MACROPHAGE INJURY 
 
 
Macrophage death is likely to contribute to the transformation of fatty 
streaks into advanced atherosclerotic lesions. Previous work in the laboratory 
showed that OxLDL promotes cell death in human macrophages by a 
mechanism involving intracellular peroxide formation. Here we show that 
glutathione depletion induced by OxLDL occurs independent of peroxyl radical 
formation. Our data suggest that the depletion of glutathione is the fundamental 
defect that renders macrophages susceptible to OxLDL-induced cell injury, but 
alone is not sufficient to kill macrophages. We indicate that increased protein-S-
glutathionylation is involved in OxLDL-induced macrophage death. A potentiation 
of OxLDL toxicity was observed in macrophages transfected with siRNA directed 
against either glutathione reductase or glutaredoxin. Our data suggests that 
OxLDL-induced cell injury in human macrophage is mediated by the depletion of 
GSH, a decreased in the GSH/GSSG ratio and peroxyl radical formation. All 
three signals are required for OxLDL-induced macrophage death. Our results 
also show that the glutathione reductase/glutaredoxin system protects 
macrophages from OxLDL-induced cell death. 
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CHAPTER ONE 
INTRODUCTION 
 
Background 
 Atherosclerosis is a disorder of lipid metabolism as well as a chronic 
inflammatory disease. Complications of atherosclerosis are the most common 
causes of death in western countries. The molecular mechanisms for 
pathogenesis of atherosclerosis have been widely investigated. Recent studies 
indicate that atherosclerosis can be considered a form of chronic inflammation 
resulting from interaction between modified lipoproteins, monocyte-derived 
macrophages, T cells, and the normal cellular elements of the arterial wall such 
as free cholesterol, cholesterol ester, triglyceride, phospholipids, and calcium salt 
content of the arteries. [1].   
 Atherosclerosis lesions begin as fatty streaks underlying the endothelium 
of large arteries. A large number of studies have implicated oxidatively modified 
LDL (OxLDL), macrophage dysfunction and cell death in the transformation of 
fatty streaks into advanced atherosclerotic lesions [2, 3]. Oxidation of LDL is 
induced by reactive oxygen species (ROS) produced by endothelial cells [4], 
vascular smooth muscle cells [5], or monocytes [6]. According to the “LDL 
retention hypothesis” by Williams and Tabas [7], LDL initially accumulates in the 
extracellular subendothelial space of arteries and, is mildly oxidized to minimally 
modified LDL. Minimally modified LDL promotes the migration of monocytes into 
the subendothelial space and their conversion into macrophages [2]. The 
increased ROS in the microenvironment convert the mildly oxidized LDL into 
highly oxidized LDL (OxLDL). OxLDL promotes lipoprotein aggregation and foam 
cell formation [8-10]. The subsequent elaboration of growth factors, secretion of 
other potent biological factors by the monocyte-macrophages, and death of the 
foam cells would result in progression of the atherosclerosis lesion [1, 2, 7]. 
OxLDL aggregation enhances OxLDL uptake and metabolism by human 
macrophages, but decreases OxLDL-induced cell injury, suggesting that OxLDL 
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aggregation may reduce vascular cell injury and necrotic core formation [11] 
(Figure 1). Taken together, oxidation of LDL and macrophage dysfunction and 
cell death play key roles in the formation and progression of atherosclerosis.  
  
  
 
 
Figure 1 Monocyte recruitment and foam cell formation. (Adapted from Glass et 
al. Cell. 2001 104(4):503-16, Ref. 1) 
 
The functional roles of OxLDL 
 In the late 1980s, Steinberg and other scientists demonstrated that the 
cells of the artery wall are constantly secreting ROS into their membranes and 
the subendothelial space [12-15]. Phospholipids contained in LDL that become 
trapped in the artery, are oxidized as a result of exposure to ROS released from 
artery wall cells.  OxLDL stimulates monocytes to attach to the endothelial cells, 
migrate into the subendothelial space and differentiate into macrophages [1, 2, 7]. 
Thus, monocyte-derived macrophages take up OxLDL via scavenger receptors 
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and OxLDL receptors such as SR-A and CD36, leading to foam cell and fatty 
streak formation which are important events in atherogenesis [3, 16, 17].  
Oxidation of LDL renders it cytotoxic for all cells involved in atherogenesis, 
including endothelial cells [18], lymphocytes [19], and monocyte-derived 
macrophages [20]. But the complex mechanism by which OxLDL induces cell 
injury is mostly unknown and the components of OxLDL which mediate cell injury 
are not clear. OxLDL contains high concentrations of lipid peroxidation products 
such as peroxides and aldehydes [21, 22]. Recent data from our lab have shown 
that OxLDL promotes peroxide formation and OxLDL-derived lipid 
(hydro)peroxides are responsible for the cytotoxicity of OxLDL in human 
macrophages [23]. Coffey and coworkers demonstrated that in fibroblasts, 
OxLDL cytotoxicity involves lipid peroxidation and iron-mediated radical formation 
[24]. Esterbauer and coworkers have shown that aldehydes, breakdown products 
of lipid peroxidation, are present in OxLDL particle and   are important 
determinants of OxLDL toxicity [22]. OxLDL has been shown to cause an initial 
decrease followed by an adaptive increase of GSH in the human monocyte cell 
line THP-1 and macrophages isolated from C3H/HEJ mice [25]. In addition, 
OxLDL promotes lysosomal damage in J-774 cells [26]. Hence, OxLDL-induced 
macrophage death may involve ROS formation, oxidative stress/antioxidant 
imbalance, alteration of thiol redox state, organelle damage, and cell lysis.  
 
Synthesis and functional roles of glutathione (GSH) 
 GSH is the predominant low molecular thiol in mammalian cells and is 
known to function in many important biological phenomena, including the 
synthesis of proteins and DNA, transport, enzyme activity, metabolism, and 
protection of cells [27]. The majority of GSH in cells is found in the cytosol at a 
concentration of 1-11 mM [28]. Cellular GSH levels reflect a steady state balance 
between GSH synthesis and combined rate of GSH consumption within the cell 
and loss through efflux or GSH conjugation. The cytosol appears to be the 
principal location of GSH de novo biosynthesis. GSH is synthesized from L-
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glutamate via two ATP-dependent enzymatic reactions that are catalyzed by γ-
glutamylcysteine synthetase (γ-GCS) and glutathione synthetase (GS) (Figure 2) 
[27, 29, 30]. GSH transported across cell membranes can be extracellularly 
converted to  γ−Glutamyl amino acids via the catalysis of γ-glutamyl transpeptides. 
γ−Glutamyl amino acids are taken up by cells and act as substrates for GSH de 
novo synthesis. GSH also can be regenerated from GSSG by glutathione 
reductase (GR) [30-32]. Various drugs have been developed to modulate GSH 
level in cells and tissues. For example, L-buthionine-sulfoximine (BSO) 
selectively inhibits γ-glutamylcysteine synthetase (γ-GCS), thereby inhibiting the 
synthesis of γ-glutamylcysteine, a precursor of glutathione. BSO inhibits GSH  
 
 
 
Figure 2 Glutathione synthesis and salvage pathways. (Adapted from A.G.Hall. 
European Journal of Clinical Investigation. 1999. 29(3):238-45, Ref. 30)  
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biosynthesis and causes depletion of cellular GSH levels [33-36]. Although 
cytosolic GSH synthesis is blocked, the cell’s use of GSH, the export of oxidized 
glutathione (GSSG), and the reduction of GSSG by glutathione reductase 
continue. GSH can also be depleted by the alkylating agent diethyl maleamide 
(DEM). Unlike BSO, DEM combines with free thiols to prevent the use of GSH, 
but not its synthesis [34]. 
GSH can directly scavenge free radicals. For example, GSH reacts rapidly 
and nonenzymatically with hydroxyl radical, the cytotoxic Fenton reaction product, 
and with N2O3 and peroxynitrite, cytotoxic products formed by the reaction of 
nitric oxide with O2, respectively [37-40]. But it does not easily react with other 
more common ROS such as superoxide and H2O2 [41]. GSH also acts as a 
substrate for glutathione peroxidase (GPx), glutathione-S-transferase (GST) and 
glutaredoxin (GRx) during the detoxification of hydrogen peroxide (H2O2), lipid 
hydroperoxides, electrophilic compounds and S-glutathionylated proteins [31, 37]. 
Each of these reactions leads directly or indirectly to the formation of glutathione 
disulfide (GSSG), a species that is reduced intracellularly to GSH by glutathione 
reductase (GR) in a NADPH-dependent reaction. At normal levels of oxidative 
and nitrosative stress, GR activity and NADPH availability are sufficient to 
maintain [GSH]/[GSSG] > 100 in the cytosol in most cells and tissues. But under 
pathophysiological conditions such as   cardiovascular and neurodegenerative 
diseases, the oxidative stress levels increase sufficiently or other factors limit the 
reaction of GR to induce an increase of GSSG, GSSG may accumulate and the 
redox balance can shift toward an oxidizing milieu [42]. This has two important 
consequences: i) the thiol redox status of the cell will shift, activating certain 
oxidant response transcriptional elements such as protein-1 transcription factor 
(AP-1) and nuclear factor kappa B (NFκB) [43, 44] and ii) GSSG may be 
preferentially secreted from the cell. The shift in the ratio of GSH/GSSG would 
change the redox state to a more positive potential. Export of GSSG would 
prevent this shift and protect cells and tissues from oxidative stress. Two GSSG 
transport systems, ATP-driven and carrier-mediated mechanisms have been 
proven to regulate the GSSG transport [45, 46].  Because GSSG is not taken up 
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by cells, but is rather degraded extracellularly, loss of GSSG from cells under 
conditions of oxidative stress increases cellular requirements for de novo GSH 
synthesis [47]. 
  
Reversible protein S-glutathionylation 
 Numerous proteins contain sulfhydryl groups (PSH) due to their cysteine 
content. In fact, the concentration of PSH groups in cells and tissues is much 
greater than that of GSH [48, 49]. A crucial component of the cellular redox 
balance is modulation of the thiol disulfide status of critical cysteine residues on 
proteins. Reactive oxygen/nitrogen species (ROS/RNS) induce cysteine 
oxidation upon reaction between the protein thiol groups and low-molecular-mass 
thiols (S-thionylation), particularly with GSH (S-glutathionylation) to produce 
protein-mixed disulfide (PSSG). GSH is the most abundant low-molecular-mass 
thiol in mammalian cell and is the dominant ligand in this reaction. Removal of 
the thiol adduct through chemical or enzymatic reduction of S-glutathionylated 
protein is defined as deglutathionylation. Glutathionylation/deglutathionylation 
reactions have two major functions: i) modification of the functional capacity of 
the protein and ii) Protection against irreversible changes caused by oxidative 
modification. In many reports, S-glutathionylation is characterized as an inhibitory 
modification whereby deglutathionylation reverses the modification and restores 
activity [50]. Examples are protein tyrosine phosphatase 1B (PTP1B) [51, 52] and 
nuclear factor kappa B (NF-κB) [53]. However, in a number of cases S-
glutathionylation activates proteins, e.g., HIV-1 protease, microsomal glutathione 
S-transferase [54, 55]. Irreversible modifications induced by oxidative stress are 
generally associated with permanent loss of protein function and may lead to 
either the progressive accumulation of the damaged proteins, as observed in 
age-related neurodegenerative disorders or their degradation. It is also 
hypothesized that cells use glutathionylation to protect the protein thiols from 
protein-protein disulfide crosslinking or other forms of permanent oxidative 
damage during oxidative stress until a repair enzyme system can de-thiolate the 
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PSSG and restore the original structure and function of the protein [55]. For 
example, aldehydes derived from the peroxidation of polyunsaturated fatty acids, 
may covalently react with functional groups of the IkB kinase (IKK), the kinase 
responsible for the activation of NFκB, thereby causing irreversible loss of IKK 
function and dysregulation of signaling pathways involved in activation of NFκB 
[56, 57]. However, reversible S-glutathionylation of IKK acts as a cellular 
regulatory mechanism of signal transduction [58]. 
  Accumulations of protein-SSG have been reported in different cell types 
including myocytes, macrophages, and hepatocytes when they are exposed to t-
butyl hydroperoxide, menadione, or diamide to model the effects of oxidative 
stress [59-61]. Protein S-glutathionylation/deglutathionylation is a dynamic 
process that occurs under physiological conditions in cells. Increased levels of 
PSSG also can occur under physiologic circumstances, during the respiratory 
burst in human neutrophils [62]. Protein S-glutathionylation/deglutathionylation 
status depends on the redox state of the GSH-system in the cell [63]. 
Identification of specific mechanism for PSSG formation remains under active 
investigation. Several mechanisms have been proposed for PSSG formation:  
(1) PS? + GSH → PSSG + O2?- + H+ 
(2) PSOH + GSH → PSSG + H2O 
(3) PSH + GSSG ↔ PSSG + GSH 
Mechanism 1: Reactive oxygen species (ROS) as inducers of S-glutathionylation 
[reaction (1) and (2)]. Direct oxidation of protein cysteine by ROS generates a 
reactive protein thiol intermediate such as a thiyl radical (PS?) or sulfenic acid 
(PSOH), which further reacts with GSH to form the mixed disulfide [64]. This 
mechanism derives from the intriguing observation that S-glutathionylation may 
occur in intact cells in various experimental models of ROS generation without 
any detectable changes in the GSH/GSSG ratio [65, 66]. 
Mechanism 2: Redox-dependent S-glutathionylation [reaction (3)]. Mixed 
disulfide formation occurs in response to changes in the GSH/GSSG ratio 
through a thiol-disulfide exchange mechanism. In models of oxidative stress, 
transient shifts in the GSH/GSSG ratio from 100 to 10 even 1 have been 
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described and found to correlate with the amount of protein mixed disulfide 
formation [67-69]. For example, a pronounced change in the GSH/GSSG was 
observed recently in an erythrocyte model of oxidative stress-induced 
haemoglobin S-glutathionylation [70]. But this mechanism is not favored by many 
people. Large shifts in the intracellular redox potential are believed to be unlikely 
to occur under normal physiological condition [49] because of the capability of 
cells to efflux of GSSG as protective mechanism against oxidative stress [71]. 
 
Glutaredoxin (GRx) and glutathione reductase (GR) system 
 An abundance of data from biochemical studies supports S-
glutathionylation/deglutathionylation as a homeostatic mechanism for protecting 
and restoring function of proteins altered by oxidative conditions. Proteins 
undergo S-glutathionylation under conditions of oxidative stress as described 
above. Reversal of S-glutathionylation (dethiolation or deglutathionylation) could 
be achieved by either changes in the intracellular redox status such as increases 
in the GSH/GSSG ratio, reduced thiols, or via enzymatic reduction by members 
of the thiol-disulfide oxidoreductase (TDOR) family including the thioredoxin (TRx) 
system and glutaredoxin (GRx) system [63, 72]. GRx is a 12-kDa cytosolic 
protein that has been characterized in vitro as a specific catalyst for the reduction 
of protein-glutathionyl-mixed disulfides (PSSG) [73-75]. Likewise, TRx has also 
been shown to specifically catalyze the reduction of inter- or intra-protein-protein 
disulfides and sulfenic acid formation of cysteine moieties of proteins [55, 76]. In 
particular, Mieyal and coworkers found that GRx is specific for PSSG, and the 
catalytic intermediate GRx-SSG is selectively recycled to the reduced enzyme by 
GSH, with formation of GSSG and regeneration of GSH by coupling with NADPH 
and glutathione reductase (GR) [42, 77] (Figure 3). These characteristic 
interactions of GRx with GSH distinguish it from TRx, which favors intramolecular 
disulfide substrates and is turned over by NADPH and thioredoxin reductase 
(TRxR), independently of GSH [76, 78]. GRx enzyme has served as a focal point 
and important tool for evolution of mechanism of reversible S-glutathionylation 
 9
because of its characterization as a specific and efficient catalyst of 
deglutathionylation of PSSG. Hence, much attention has been paid to the 
deglutathionylation of GRx. Recently some interesting findings characterized 
GRx as a versatile catalyst, capable of facilitating S-glutathionylation. For 
example, it has been shown that GRx can mediate S-glutathionylation of protein 
tyrosine phosphatase 1B (PTP1B) under certain conditions such as H2O2 
treatment [77, 79].  
 
 
Figure 3. General mechanism of the glutaredoxin system. (Adapted from Melissa 
D. Shelton et al. Antioxidants and Redox Signaling. 2005.7(3-4):348-66, Ref.77)  
 
Hypothesis and objectives of the present study 
Macrophage death is likely to contribute to the transformation of fatty 
streaks into advanced atherosclerotic lesions. A large number of studies have 
implicated oxidatively modified LDL (OxLDL) in macrophage and foam cell death, 
but the underlying mechanism is not fully understood. Previously, our lab showed 
that OxLDL promotes cell death in human macrophages by a caspase-3 
independent mechanism involving intracellular peroxide formation, mitochondrial 
dysfunction and subsequent loss of plasma membrane integrity. The oxidation of 
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LDL produces a complex mixture of lipid hydroperoxides, oxysterols, and 
aldehydes [80-82]. Asmis et al. pointed out that the precursors of peroxyl radicals 
are most likely lipid hydroperoxides, particular 7-hydroperoxyl cholesterol [23]. 
There are two possible ways by which hydroperoxides enter the cell: i) Uptake of 
the entire OxLDL particle or ii) selective uptake of only the lipid hydriperoxides 
[83]. However, Asmis et al. demonstrated that peroxyl radical formation alone 
cannot explain OxLDL-induced macrophage death [23]. In primary human cells, 
including human macrophages, vitamin C (ascorbic acid) and glutathione are the 
principal free radical scavengers [84]. Their intracellular concentrations are 
typically between 1 – 10 mM. In culture, however, vitamin C is rapidly depleted 
from human monocyte-derived macrophages, leaving glutathione as the only 
major antioxidant in the aqueous compartments. Because OxLDL promotes 
sustained intracellular oxidative stress in macrophages [84], it is expected that 
glutathione redox state to be compromised in cells exposed to OxLDL. In vitro, 
exposure of the monocyte cell line THP-1 and macrophages isolated from 
C3H/HEJ mice to OxLDL results in an initial depletion of GSH [25].  The 
components of OxLDL which are mediating the decrease of GSH are unclear. 
Since 4-HNE, an aldehyde, can elicit a similar response, it is likely that 4-HNE or 
other aldehydes in the OxLDL particle contribute to OxLDL-induced macrophage 
death [25]. We therefore hypothesized that 1) in addition to peroxide formation 
OxLDL-induced macrophage death involves change in the glutathione redox 
state induced by 4-HNE or other aldehydes.  
Alterations in the celluar redox state can promote protein-S-
glutathionylation (PSSG). Accumulation of PSSG also has been reported in 
different cell types under oxidative stress such as H2O2 [66, 85, 86]. Significant 
increases in PSSG have been found in human diseases such as hyperlipidemia 
[87], chronic renal failure [88], and diabetes mellitus [87-90]. We therefore 
hypothesized further that 2) OxLDL promotes the accumulation of PSSG that 
may contribute to OxLDL-induced macrophage death.  
Since GRx enzyme is the primary intracellular catalyst of 
deglutathionylation of PSSG [73-75]. GR and GSH are required for its 
 11
regeneration [42]. We finally hypothesized that 3) inhibition of the Grx and/or GR 
sensitizes human macrophages to OxLDL-induced cell injury.  
 The goal of this study was to investigate whether OxLDL alters the thiol 
redox state of human macrophages, whether changes in the thiol redox state are 
both necessary and sufficient to promote macrophage death, and to determine 
whether the glutathione reductase/glutaredoxin system plays a key role in 
protecting macrophages from OxLDL-induced cell injury.  
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Chemicals 
1,3-bis[2-Chloroethyl]-1-nitrosourea (BCNU), L-Buthionine-[S,R]-
Sulfoximine (BSO), Triton X-100, Diethyl maleate (DEM), Dithiothreitol (DTT), N-
ethyimaleimide (NEM), o-phthalaldehyde (OPA), reduced glutathione, 6-Hydroxy-
2,5,7,8-tetremethyl-chroman-2-carboxylic acid (Trolox), HEPES, Tris-HCl, 
Sodium Phosphate, Potassium Phosphate, NaCl and KCl were purchased from 
Sigma-Aldrich-Fluka (St. Louis, MO). Acetonitrile, Methanol and Propionic Acid 
were purchased from Fisher Scientific (Pittsburgh, PA). [3H]-adenine was 
supplied by Amersham Biosciences Corp. (Piscataway, NJ). Culture medium 
(RPMI),  GLUTAMAX-1, 1% v/v nonessential amino acids, 1 mmol/L Sodium 
Pyruvate were purchased from  Gibco BRL (Carlsbad, CA ). Aprotinin, Leupeptin, 
4-hydroxynonenal (4-HNE) were from Calbiochem (La Jolla, CA)  
 
Isolation and culture of human monocyte-derived macrophages 
Human mononuclear cells were isolated from buffy coats by density 
gradient centrifugation, and purified, as described elsewhere [91]. Buffy coats 
were washed to remove platelets before they were layered on Ficoll. After 
gradient centrifugation, mononuclear cells were collected and washed to remove 
Ficoll. Washed mononuclear cells were resuspended in culture medium 
containing 15% human AB serum and incubated in Teflon bags for 14 days. 
Subsequently, the monocyto-derived human macrophages were incubated for 2 
hours on Aclar (22-mm diameter, transparent fluorinated-chlorinated 
thermoplastic film, ProPlastics) in 12-well plates at a density of 0.15x106 
cells/well for all other experiments. After removal of nonadherent cells by washing, 
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adherent macrophages were incubated in culture medium containing 5% human 
AB serum for 48 hours prior to use. 
 The cell culture medium consisted of RPMI 1640 (Gibco BRL) 
supplemented with 2 mmol/L L-alanyl-L-glutamine (GLUTAMAX-1), 1% v/v 
nonessential amino acids, 1 mmol/l sodium pyruvate,  100 U/l Penicillin and 100 
µg/ml Streptomycin and 10 mmol/l HEPES (Fluka).  All solutions were routinely 
tested for endotoxin.   
 
Lipoproteins 
 Human LDL was prepared by ultracentrifugation, using a TL-100 
ultracentrifuge (Beckman Instruments) equipped with a TLA-100.4 fixed-angle 
rotor, as described previously [92]. The LDL fraction was concentrated with a 
centrifugal filter device (Centricon-100 concentrators from Amicon) and was 
further purified by gel filtration chromatography on excellulose GF-5 columns 
(Pierce). LDL was sterilized by filtration through a 0.2 µm pore size syringe filter. 
LDL was then diluted in phosphate-buffered saline (PBS) to a protein 
concentration of 3 mg/ml and was oxidized for 24 hours at 37°C with 25 µmol/l 
CuSO4 as described by Esterbauer et al [93]. The freshly prepared OxLDL was 
concentrated by ultrafiltration in Centricon-100 concentrators (Amicon), and 
further purified by size exclusion chromatography on excellulose GF-5 columns 
(Pierce). Protein concentrations of all LDL samples were determined with 
bicinchoninic acid (Pierce) using bovine serum albumin as a standard. 
 
Generation of siRNA  
 Small interfering RNA (siRNA) directed against glutathione reductase, 
glutaredoxin, respectively, was prepared with the Dicer siRNA Generation Kit 
(Gene Therapy Systems, Eugene, OR). Template DNA for transcription was 
generated by PCR from plasmids carrying either human glutathione reductase 
gene obtained from Dr. Dieter Werner (University of Heidelberg, Germany), or 
human glutaredoxin gene kindly provided by Dr. John J. Mieyal (Case Western 
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Reserve University). Double-stranded RNA was synthesized with the T7 enzyme 
mix and 22bp siRNA was prepared using recombinant Dicer enzyme according 
to the manufacturer’s instructions. The siRNA were column purified and RNA 
concentrations were measured with the RiboGreen RNA Quantification Kit 
(Molecular Probes, Eugene, OR). Human macrophages were transfected for 6 
hours at 37°C with 0.5 µg siRNA. Transfection was performed under serum-free 
conditions with the lipid-based GeneSilencer siRNA transfection reagent (Gene 
Therapy Systems, Eugene, OR). FITC-labeled siRNA directed against luciferase 
GL2 (Dharmacon, Lafayette, CO) served as both a transfection and Negative 
control in siRNA experiments. 
 
Glutaredoxin activity assay 
24 hours after macrophages (150,000/well) were transfected with siRNA, 
the cells were cultured in RPMI for another 24 hours. The medium was removed. 
200 µl lysis buffer (adapted from Ref. 42) (50 µM Tris-HCl, 2.2 µM sodium 
phosphate, 0.7 µM potassium phosphate, 369 µM NaCl, 1.35 µM KCl, 1% (w/v) 
Triton X-100, 10 µg/ml leupeptin, 20 µg/ml aprotinin, 2 µl/ml DMSO) was added 
to each well and the plates were gently shaken for 10 min at 4°C. The lysates 
were collected and cleared by spinning. Protein content was measured with the 
DC Lowry kit from Biorad using BSA as standard. 
Glutaredoxin activity was assayed using the standard radiolabel method 
[74] by our collaborator, Dr. Mieyel. Briefly, an aliquot of BSA-SSG[35S] was 
added to prewarmed lysate (30°C) with yeast glutathione reductase (GR) (Sigma, 
St. Louis, MO)  (2 units/ml, final). Addition of ice-cold trichloroacetic acid (10%, 
final) precipitated the assay mixture at 0.5, 1, 2, and 3 min. After centrifugation, 
the supernatants were analyzed for [35S] by scintillation counting. Glutaredoxin 
activity is presented as the total rates of deglutathionylation which are the slopes 
of [35S]GSH released versus time. The rates were expressed as nanomoles of 
product/min/mg of cellular protein [42]. 
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Glutathione reductase activity assay 
Macrophage lysates were prepared with 50 mM KPi, pH 7.5, containing 1 
mM EDTA and 1% Triton X-100. The assay was performed at 37°C in 50 mM 
KPi, pH 7.5, containing 1 mM EDTA, BSA (1 mg/ml), 333 µM NADPH. The 
enzymatic reaction was started by addition of 1mM GSSG and absorbance was 
monitored at 340 nm for 15 min on a VERSAmax plate reader (Molecular 
Devices, Sunnyvale, CA). Glutathione reductase from Baker’s yeast served as a 
standeard. 
Measurement of cellular DNA 
 The quantity of DNA was determined fluorometrically using the PicoGreen 
DNA Quantization Kit (Molecular Probes, Eugene, OR). Fluorescence was 
measured in a FUSION plate reader (Packard) at an excitation wavelength of 
485 nm and an emission wavelength of 535 nm. The amount of DNA marks the 
cell numbers. 
Cytotoxicity assay  
 Cytotoxicity of OxLDL to human macrophages was estimated by 
measuring leakage of radioactivity from cells pre-loaded with [8-3H]adenine (1 
mCi/ml, Amersham), as described by Reid and Mitchinson [94]. Macrophages 
were loaded with [8-3H]adenine in culture medium with 5% human AB serum for 
2 hours and washed twice with PBS for 5 min at 37°C. After cell stimulation, 
medium of samples were assessed for radioactivity using a liquid scintillation 
counter. Intracellular radioactivity was determined by lysing the cells with 1% (w/v) 
Triton X-100 followed by liquid scintillation counting. Leakage of radioactivity into 
the medium was calculated as a percentage of the total. Total radioactivity per 
well was always proportional to the cell number, as determined by DNA 
measurement. Control experiments also confirmed that adenine loading did not 
interfere with any of the other assays. 
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Determination of cellular glutathione  
 Macrophages were rinsed with PBS and scraped off the Aclar. Each 
sample was divided into three equal aliquots (500 µl). One was used for the 
determination of DNA as a measure of cell number. One was used for the 
determination of oxidized glutathione (GSSG) and the last one was used for the 
determination of total glutathione (GSH+GSSG). Samples were prepared 
according to Senft et al [95] with modifications. Briefly, the samples designated 
for GSSG determination were supplemented with N-ethylmaleimide (6 mM) to 
alkylate free thiol groups. Proteins were precipitated with 100 µl 20% TCA in 20 
mM HCl. 250 µl 1 M KPi (pH 7.0) was added to 150 µl clean supernatants to 
neutralize the pH value. The resulted sample was diluted with 250 µl 0.1 M KPi 
(pH 7.0) and further reduced with fresh DTT (final concentration 9 mM) for 60 min 
at room temperature. Glutathione was conjugated with 3.7 mM o-phthalaldehyde 
and separated by reverse phase HPLC as described by Paroni et al [90]. HPLC 
separation was performed on a Jasco HPLC system equipped with a 
spectrofluorometer (FP-920, Jasco Inc.). The excitation and emission wavelength 
were set at 340 nm and 420 nm, respectively. Glutathione was separated with an 
isocratic solution (21 mM propionate in 36 mM Na/Pi buffer (pH 6.5)/acetonitrile, 
95:5 by vol.) on a Brownlee 22 cm C18 ODS analytical column (5 µm) protected 
by a Browmlee 3 cm C18 ODS guard column (5 µm). Flow rate was 1.2 ml/min. 
Levels of reduced glutathione (GSH) were calculated as the difference between 
GSH+GSSG and GSSG. 
 
Determination of protein-bound glutathione  
 Macrophages were collected by scraping after being washed with PBS. 
Each sample was split into two aliquots, one for the determination of DNA (500 µl) 
and one for the determination of protein-bound glutathione (1000 µl, PSSG). 
Proteins were precipitated by TCA solution as described before. Protein pellets 
were dissolved in 150 µl 0.1 M NaOH and diluted with 250 µl 1 M KPi (pH 7.0). 
Glutathione was released by reduction with 14 mM DTT for 1 hour at room 
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temperature. Proteins were precipitated by TCA solution, and the supernatants 
were analyzed for glutathione, as described above. 
 
Statistics 
 All data points shown are means ± SE of triplicate determinations from 5 
independent experiments unless stated otherwise. Data were compared among 
groups using an unpaired t-test for two groups or one way ANOVA for multiple 
groups. Results were considered significant at the P < 0.05 level. Statistical 
analysis was performed utilizing SigmaStat (SPSS). 
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CHAPTER THREE 
RESULTS 
 
OxLDL-induced macrophage death and alterations in the thiol redox state 
 We first examined the effect of OxLDL on the thiol redox state of human 
macrophages. We found that changes in the thiol redox state occurred prior to 
macrophage death. The GSH/GSSG ratio is one of the principal determinants of 
cellular redox state, and alterations in the redox state can lead to cellular 
dysfunction and cell death [33]. To determine whether OxLDL altered the thiol 
redox state in macrophages, we measured intracellular GSHtot and GSSG levels 
in macrophages in the early (24 hours) of OxLDL toxicity. Levels of reduced 
glutathione (GSH) were expressed as the difference between GSHtot and GSSG. 
The ratio of GSH/GSSG was calculated using reduced glutathione (GSH) level 
divided by GSSG level. OxLDL at 10 µg/ml, 25 µg/ml, and 50 µg/ml decreased 
the GSH/GSSG ratio by 13%, 26% and 40%, respectively. But this decrease in 
the GSH/GSSG ratio was not accompanied by a statistically significant decrease 
in macrophage viability (Figure 4A). However, we showed previously that the 
dose-response curve for OxLDL-induced cell death shifts to the left when 
incubation time  increased to 48 h or 72 h [23], indicating that significant 
alterations in the celluar redox state precede the onset of macrophage death. 
After 72 hours of OxLDL treatment, all macrophages had lysed [23].  
Both increased accumulation of GSSG and loss of GSH, e.g. due to GSH 
efflux or GSH conjugation, can contribute to decreases in the GSH/GSSG ratio 
[96]. While we observed a dose-dependent decrease in GSH, surprisingly we did 
not observe a significant increase in GSSG level (Figure 4B), implying that in 
human macrophages the OxLDL-induced decreases in the GSH/GSSG ratio 
were primarily due to a depletion of GSH rather than an increased accumulation 
of GSSG.  
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Figure 4A: Effects of OxLDL on cell viability (?) and the GSH/GSSG Ratio (▲). 
Macrophage viability was assessed with the [3H]adenine release method after 
stimulation with OxLDL for 24 hours. Cytotoxicity is expressed as the percentage 
of total cellular radioactivity released into the supernatant. Total cellular 
radioactivity was measured after cell lysis in the presence of 1% (w/v) Triton X-
100 with scintillation counting. Determinations of GSHtot and GSSG were 
performed as described in “Material and Methods”. Levels of reduced glutathione 
(GSH) were calculated as the difference between GSHtot and GSSG.  Results are 
expressed as mean ± SE. *P < 0.05 vs control without OxLDL treatment. 
 
Next, we examined whether the decrease in intracellular GSH results from 
GSH efflux. Cells may release glutathione into the extracellular space. Reduced 
GSH is the major transport form which plays a significant role in GSH turnover 
[97]. The release of GSSG has also been observed under conditions of oxidative 
stress in different cell types including erythrocytes [98] and eye lens [99]. As 
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predicted, the extracellular GSHtot level was increased when cells were treated 
with 10 µg/ml and 25 µg/ml OxLDL. However, after OxLDL concentration was  
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Figure 4B: Effects of OxLDL on intracellular GSHtot (?) and the GSSG level (▲). 
Intracellular GSHtot and the GSSG level were determined as described in 
“Material and Methods”. Results are expressed as mean ± SE. *P < 0.05 vs 
control without OxLDL treatment. The dotted line represents the concentration of 
GSH determined by HPLC in the culture medium. 
 
increased to 50 µg/ml, GSHtot exhibited similar level to that at 0 µg/ml OxLDL 
treatment, indicating that GSH efflux had stopped at that point. Nevertheless, 
when the concentration of OxLDL was increased to 75 µg/ml, the decrease in 
intracellular GSH level may be due to cell leakage. Therefore, our data suggest 
that GSH efflux does not appear to contribute to OxLDL-induced decreases in 
the GSH/GSSG ratio. 
Another explanation for the decrease in GSH would be GSH conjugation 
with aldehydes. Several reports suggest that glutathione can conjugate with 
 21
aldehydes and be exported from the cell [71, 100, 102]. OxLDL has been shown 
to cause an initial decrease of GSH in the human monocyte cell line THP-1 and 
macrophages isolated from C3H/HEJ strain of mice [25].  This fall in glutathione 
occurs as a result of its oxidation or conjugation with aldehydes and exportation 
from the cell [25]. To examine whether 4-HNE has an effect similar to OxLDL, 
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Figure 5: Effects of OxLDL on intra- and extra-cellular levels of glutathione. 
[3H]Adenine-loaded human monocyte-derived macrophages were incubated for 
24 hours with OxLDL at the indicated concentrations. Intracellular GSH+GSSG 
(▲) were measured as described in “Material and Methods”. The culture medium 
was used to determine extracellular GSH + GSSG (?).  Results are expressed 
as mean ± SE. *P < 0.05 vs control without OxLDL treatment. 
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we measured cell viability, the GSH/GSSG ratio, and GSHtot level in 
macrophages treated with increasing dose of 4-HNE for 24 hours . We found that 
4-HNE-induced macrophage death appeared to be preceded by and correlate to 
a dose-dependent decrease in the GSH/GSSG ratio (Figure 6A). As expected, 
both GSHtot levels and GSSG level decreased (Figure 6B). However, the 
decrease in the GSH/GSSG ratio indicates that GSSG levels 
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Figure 6A: Effects of 4-HNE on cell viability and the GSH/GSSG Ratio. 
[3H]Adenine-loaded human monocyte-derived macrophages were incubated for 
24 hours with 4-hydroxynoneal (4-HNE) at the indicated concentrations. Cell 
viability (?) and the GSH/GSSG ratio (▲) were determined as described in 
“Material and Methods”. Results are expressed as mean ± SE. *P < 0.05 vs 
control without 4-HNE treatment. n=4 
 
decreased proportionally slower than GSH. The slower decrease in GSSG may 
result from suppressed activity of glutathione reductase (GR) by 4-HNE. Added 
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4-HNE decreased the GSH level and GSH/GSSG ratio at the onset of 
macrophage death, similar to the effects observed with OxLDL treatment, i.e. a 
two-fold decrease in GSH, and a two-fold decrease in the GSH/GSSG ratio 
(Figure 6A). The data suggested that 4-HNE or other aldehydes present in 
OxLDL may account for the depletion of GSH observed during OxLDL-induced 
macrophage death.  
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Figure 6B: Effects of OxLDL on intracellular GSHtot (?) and the GSSG level (▲). 
Intracellular GSHtot and the GSSG level were determined as described in 
“Material and Methods”. Results are expressed as mean ± SE. *P < 0.05 vs 
control without 4-HNE treatment. n=4 
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Role of GSH depletion in OxLDL-induced macrophage death 
 Having demonstrated that the depletion of GSH contributes to OxLDL-
induced macrophage death, we studied whether the depletion of GSH was  
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Figure 7A: Effect of DEM, BSO and OxLDL on glutathione levels in macrophages. 
[3H]Adenine-loaded macrophages were preincubated  for 2 h  in  either medium 
alone or the thiol alkylating agent diethyl maleate (DEM, 1 mM). Cell were then 
treated for 24 hours with either medium only (?) or with OxLDL (75 µg/ml) (?). 
The GSH synthesis inhibitor buthionine sulfoximine (BSO, 0.3 mM) was present 
where indicated. GSHtot was determined as described in “Material and Methods”. 
Results are expressed as mean ± SE. *P < 0.05 vs control without OxLDL 
treatment. n=3 
 
sufficient to cause macrophage death. Buthionine sulphoximine (BSO) is an 
inhibitor of  γ-glutamyl-cysteinesynthetase (γ-GCS) and has been used in a 
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number of biochemical and pharmacological studies as a specific agent for 
inhibiting GSH biosynthesis and thereby induce GSH depletion [102]. Another  
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Figure 7B: Effect of glutathione depletion on OxLDL-induced macrophage injury. 
To reduce intracellular glutathione levels, [3H]Adenine-loaded macrophages were 
preincubated for 2 hours in  either medium alone or the thiol alkylating agent 
diethyl maleate (DEM, 1 mM). Cell were then treated for 24 hours with either 
medium only (?) or with OxLDL (75 µg/ml) (?). The GSH synthesis inhibitor 
buthionine sulfoximine (BSO, 0.3 mM) was present where indicated.  
Macrophage viability was measured as described in “Material and Methods”. 
Results are expressed as mean ± SE. *P < 0.05 vs control without OxLDL 
treatment. n=3 
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widely used drug diethyl maleamide (DEM) depletes GSH through its conjugation 
with GSH [103, 104]. Kuzuya and coworkers reported that a decrease in the GSH 
levels induced by the pre-treatment of cells with BSO enhanced the cytotoxicity 
of OxLDL in vascular endothelial cells [105]. To determine the role of GSH 
depletion in macrophage injury, we utilized BSO and DEM to reduce intracellular 
GSH level. Macrophages were preincubated for 2 hours in either medium alone 
or 1 mM DEM prior to be treated for 24 hours with either medium only or with 
OxLDL (75 µg/ml) in presence or absence of  BSO (0.3 mM). Macrophages 
intracellular GSH level (Figure 7A) and viability were then measured (Figure 7B). 
DEM, and DEM plus BSO in the absence of OxLDL depleted GSHtot by 23.1% 
and 92.4%, but cell viability was not significantly decreased. This result indicates 
that despite low GSHtot level, cytotoxicity is not elevated confirming that GSH 
depletion alone is not sufficient to promote macrophage death in the absence of 
oxidative stress. Addition of OxLDL dramatically increased cell cytotoxicity in 
cells incubated with DEM+BSO compared with other treatments, suggesting that 
the depletion of GSH potentiated macrophage injury induced by OxLDL. 
Furthermore, DEM and DEM+BSO depleted GSHtot and GSSG level, resulting in 
an increase in the GSH/GSSG ratio from 27 to 33 and 45, respectively (data  not 
shown). The increase in the GSH/GSSG ratio indicates that GSSG levels 
decreased proportionally faster than GSH. The possible explanation is that 
glutathione reductase (GR) is more effective without OxLDL toxicity, thereby 
converting more GSSG to reduced GSH. 
To further investigate whether the decreased GSH/GSSG ratio was 
independent of the formation of peroxyl radical, we loaded cells with 250 µΜ 
Trolox which is a peroxyl radical scavenger to inhibit the formation of peroxyl 
radical.  Previously, our lab demonstrated that addition of OxLDL accelerated the 
rate of intracellular ROS formation by 3.6 fold and this increase was inhibited by 
93% in the presence of the peroxyl radical scavenger Trolox [23]. Here we show 
that Trolox restored cell viability in OxLDL-treated macrophages, but restored 
neither GSHtot level nor the GSH/GSSG ratio (Figure 8), indicating that the 
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decreases in the GSHtot and the GSG/GSSG ratio were independent or upstream 
of the peroxyl radical formation.  
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Figure 8: Effect of Trolox on OxLDL-induced alterations in cell viability, GSHtot 
Levels and the GSH/GSSG ratio. [3H]Adenine-loaded macrophages were treated 
for 24 hours with either medium only (?) or with OxLDL (75 µg/ml) plus Trolox 
(250 µM) (?). Cell viability, GSHtot and the GSH/GSSG ratio were determined as 
described in “Material and Methods”. Results are expressed as mean ± SE. *P < 
0.05 vs control without Trolox treatment. 
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Protein-S-glutathionylation may mediate OxLDL-induced macrophage 
death 
Both increased ROS formation and changes in the thiol redox potential, i.e. 
accumulation of GSSG or decreased GSH/GSSG ratio, can induce protein-S-
glutathionylation [85]. We therefore investigated whether protein-S- 
glutathionylation may involve in OxLDL toxicity. To this end, macrophages were 
exposed to OxLDL (100 µg/ml) for 24 hours. Cell cytotoxicity and PSSG levels 
were measured. OxLDL alone killed macrophages (Figure 9A), but did not 
significantly increase PSSG (Figure 9B). However, it is possible that PSSG have 
either leaked out of the macrophages or the increase in PSSG was limited to a 
few selected proteins and overall made make up <<10% of macrophage proteins. 
To promote the accumulation of PSSG and enhance the detectability of PSSG 
formed, we preincubated macrophages for 1 hour with 0.2 mM 1,3-bis[2-
chloroethyl]-1-nitrosourea (BCNU), a glutathione reductase (GR) inhibitor, which 
causes the accumulation of GSSG and therefore limites the ability of Grx to 
deglutathionylate PSSG [99]. Subsequently, macrophages were exposed to 
OxLDL (100 µg/ml) for 24 h. Interestingly, BCNU alone had no effect on cell 
cytotoxicity or PSSG, but potentiated both OxLDL-induced PSSG formation 
(Figure 9A) and cytotoxicity (Figure 9B), demonstrating that PSSG accumulation 
is not detectable unless GR is blocked by BCNU. However, inhibition of GR by 
BCNU may cause sufficient GSSG accumulation to promote non-enzymatic, 
formation of PSSG. However, that is unlikely as this reaction generally only 
occurs at the GSH/GSSG ratios < 10 [77]. 
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Figure 9A:  Effect of BCNU, and Trolox on macrophage death. Human 
macrophages were incubated either in the absence or presence of OxLDL (100 
µg/ml) or OxLDL+BCNU (0.2 mM). Trolox (250 µM) was present where indicated.  
Macrophage cytotoxicity was measured as described in “Material and Methods”. 
Results are expressed as mean ± SE. *P < 0.05 vs control without OxLDL, BCNU 
and Trolox treatments. n=3 
 
 
Alternatively, enhanced ROS formation may oxidize PSH into PSOH, 
which readily reacts with GSH to form PSSG. Under conditions of limited 
deglutathionylation, i.e. with BCNU present, this would lead to the accumulation 
of PSSG. To determine whether OxLDL-induced ROS contributes to PSSG 
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formation in OxLDL-induced macrophages, macrophages were exposed to 
OxLDL (100 µg/ml) for 24 hours in the absence or presence of the potent peroxyl  
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Figure 9B:  Effect of BCNU, and Trolox on macrophage P-SSG level. Human 
macrophages were incubated either in the absence or presence of OxLDL (100 
µg/ml) or OxLDL+BCNU (0.2 mM). Trolox (250 µM) was present where indicated. 
PSSG were analyzed as described in “Material and Methods”. Results are 
expressed as mean ± SE. *P < 0.05 vs control without OxLDL, BCNU and Trolox 
treatments. n=2 
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radical scavenger Trolox. Interestingly, Trolox blocked PSSG formation and 
OxLDL-induced macrophage death. This result suggests that OxLDL–induced 
macrophage death may involve peroxyl radical mediated formation of PSOH and 
the subsequent generation of PSSG.  
A role for the glutaredoxin (GRx) in protecting macrophages from OxLDL-
induced cell injury 
OxLDL-induced protein-S-glutathionylation (Figures 9A and B) may 
contribute to macrophage injury. We therefore examined if GRx, which is the 
primary enzyme involved in the deglutathionylation of PSSG [42], is required to  
 
Table 1: Effect of siRNA directed against glutathione reductase and glutaredoxin 
on GRx activity and GR activity. siRNA directed against glutathione reductase 
and glutaredoxin were prepared with the Dicer Kit (Gene Therapy Systems, 
Eugene, OR ) and transfected into human macrophages. Lysates were prepared 
and assayed for protein content and GRx or GR activity as described under 
“Materials and Methods”. The activities are presented as nanomoles/min/mg. 
Results are expressed as mean ± SD. n=1 
 
  GR Activity 
nmol/min/mg 
GRx Activity 
nmol/min/ml 
Non-transfection 42.5±3.9 2.2±0.03 
Mock 40.9±2.5 2.3±1.4 
Anti-FITC-GL2 40.8±0.5 2.4±0.4 
Anti-GRx 40.9±0.9 0.6±1.7 
Anti-GR 38.0±1.7 2.2±3.1 
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protect macrophages against OxLDL toxicity. Macrophages were transfected with 
siRNA directed against GRx as evidenced by a 70% decrease in GRx activity 
(Table 1). We observed no difference in GRx activity in mock, anti-GR and anti-
FITC-GL2 transfected cells compared to non-transfected macrophages, 
suggesting that siRNA against GRx specifically and efficiently blocked the 
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Figure 10: Effect of siRNA directed against glutathione reductase and 
glutaredoxin on OxLDL-induced cell death. siRNA directed against glutathione 
reductase and glutaredoxin were prepared with the Dicer Kit (Gene Therapy 
Systems, Eugene, OR ) and transfected into human macrophages. Cells were 
loaded with [3H]adenine for 2 hours and washed. Mock-transfected (?) and 
macrophages transfected with siRNA directed against either GR (?) or Grx (▲) 
were incubated for 24 h with OxLDL at the indicated concentrations and cell 
viability was measured as described in “Materials and Methords”. Results are 
expressed as mean ± SE. n=4 
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expression of GRx. Importantly, when macrophages were transfected with siRNA 
against GRx or GR, the dose-dependent curves for OxLDL-induced macrophage 
death was shifted to the left (Figure 10]. Transfection of human macrophages 
with siRNA directed against luciferase GL2 showed no effect on OxLDL-induced 
cytotoxicity (data not shown). This result suggests that GRx protects 
macrophages from OxLDL toxicity.  
We also attempted to quantitate the expression level of GRx and GR in 
siRNA transfected macrophages with RNAase Protection Assay with no success 
due to the insufficient sensitivity of this method for human macrophage cells. 
 
A role for the glutathione reductase (GR) in protecting macrophages from 
OxLDL-induced cell injury 
  
Glutathione reductase (GR) is the enzyme responsible for maintaining the 
GSH/GSSG ratio by converting intracellular GSSG into GSH. GRx catalyzes the 
deglutathionylation of PSSG. GRx is recycled to the reduced enzyme by GSH, 
resulting in the formation of GSSG, which in turn is regenerated to GSH by GR 
[42]. Thus, GR plays important role in GRx turnover. We would expect that the 
inhibition of GR activity not only enhances GSSG accumulation and PSSG 
formation but also prevents the deglutathionylation of PSSG. Hence, inhibiting 
the GR would sensitize macrophages to OxLDL-induced cell injury. To test this 
hypothesis, we examined the dose dependency of OxLDL-induced macrophage 
death at the absence or presence of the GR inhibitor, BCNU. In the presence of 
BCNU, the LD50 of OxLDL decreased 2.5-fold, demonstrating that BCNU 
potentiated OxLDL-induced macrophage death (Figure 11). 
To further examine if glutathione reductase (GR) is critical in protecting 
macrophages from OxLDL-induced injury. Macrophages were transfected with 
siRNA against human GR. We observed a minor (10%) but significant decrease 
in GR activity with antiGR siRNA transfection (Table 1). There is no significant 
difference in GR activity in mock, anti-GR and anti-FITC-GL2 transfected cells 
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compared to non-transfected macrophages, suggesting that siRNA against GR 
specifically and efficiently blocked the expression of GR. As expected, the does-
dependent curve for OxLDL-induced macrophage death shifted to left for human 
macrophages transfected with siRNA directed against GR (Figure 10), 
suggesting that GR also plays a protective role in OxLDL-induced macrophage 
death.  
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Figure 11: Effect of the glutathione reductase inhibitor BCNU on OxLDL-induced 
macrophage death. [3H] Adenine-loaded macrophages were incubated for 18 
hours with OxLDL at the indicated concentrations. Then vehicle (?) or BCNU (▲) 
was added to a final concentration of 0.2 mM. Cytotoxicity was measured after 
48 hours. Results are expressed as mean ± SE. n=4 
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CHAPTER FOUR 
DISCUSSION 
 
Macrophage death is believed to be an important event in the 
pathogenesis of human atherosclerosis and can be induced by OxLDL in vitro 
[10, 20]. The mechanisms underlying OxLDL-induced macrophages death is 
unclear. In the present study, we provide evidence that OxLDL-induced cell injury 
in human macrophage is mediated by two independent signals: decreased 
GSH/GSSG ratio and peroxyl radical formation. Both signals are required for cell 
death. Furthermore, we provide evidence that macrophage death induced by 
OxLDL involves the formation of PSSG, and that the GRx/GR enzyme system 
protects macrophage from OxLDL-induced cell injury. 
Previously, we demonstrated that OxLDL-induced oxidative stress 
promotes cell lysis in human macrophages, a process that involves the formation 
of peroxides, but not superoxide [23]. Scavengers of peroxyl radicals such as 
Trolox prevent macrophage lysis, implicating peroxyl radicals in macrophage 
lysis induced by OxLDL [23]. However, peroxyl radical formation alone may not 
be sufficient to induce macrophage death because increasing the OxLDL 
concentration from 80 µg/ml to 150 µg/ml showed no further increase in the rate 
of peroxyl radical formation, yet the rate of macrophage death tripled [23]. One 
explanation could therefore be that a second signal or component of OxLDL is 
involved in OxLDL-induced macrophage damage as we discuss below. 
In this research, we show that a change of the glutathione redox state in 
human macrophages contributes to OxLDL-induced macrophage death. The 
GSH/GSSG ratio is one of the principal determinants of the cellular redox 
environment and alterations in the redox environment can lead to cellular 
dysfunction and cell death [33]. Hence, the additional signal required for OxLDL 
toxicity in addition to peroxyl radical formation may involve changes of the 
GSH/GSSG ratio. Indeed, we found that OxLDL-induced macrophage death 
inversely correlated to the GSH/GSSG ratio. After 24 hours of OxLDL treatment, 
a dose-dependent decrease in the cellular GSH/GSSG ratio preceded 
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macrophage death, indicating that significant alteration in the cellular redox state 
may lead to macrophage death.  
However, changes in cellular redox state alone, i.e. depletion of GSH or 
decreased GSH/GSSG ratio, cannot explain OxLDL-induced macrophage death. 
This conclusion is based on our observation that depletion of intracellular 
glutathione with the alkylating agent diethyl maleamide (NEM) and glutathione 
synthesis inhibitor L-buthionine-sulfoximine (BSO) alone did not promote cell 
death, but potentiated OxLDL-induced macrophage injury. This result is in 
agreement with GSH depletion studies in thymocytes, which demonstrate that 
treatment with BSO depletes GSH by 90% but is non-toxic [107, 108]. 
Interestingly, NEM and BSO+NEM increased the GSH/GSSG ratio 
accompanying with the depletion of GSH in human macrophages (data is not 
shown). Those results suggested that the GSH depletion in the absence of 
oxidative stress can not lead to the decrease in the GSH/GSSG ratio and fails to 
cause cell death, implying that the decreased GSH/GSSG ratio is required in 
OxLDL-induced cell death. Furthermore, our experiments with Trolox, a peroxyl 
radical scavenger, showed that Trolox blocked OxLDL-induced cell death, but 
restored neither intracellular glutathione levels nor the GSH/GSSG ratio, 
indicating that glutathione depletion and a decreased GSH/GSSG ratio induced 
by OxLDL occur independent or upstream of peroxyl radical formation. However, 
partial restoration of intracellular GSH stores with glutathione diethyl ester did not 
improve the GSH/GSSG ratio, but substantially reduced OxLDL toxicity (data not 
shown). Together, our data suggest that both a decrease in the GSH/GSSG ratio 
and peroxyl radical formation are required for OxLDL-induced macrophage death, 
and those two signals are independent. However, inhibition of peroxyl radical 
formation by Trolox completely restore cell viability, implying  that the depletion of 
GSH and the decreased GSH/GSSG ratio are the fundamental defect that 
renders macrophages susceptible to cell injury by the peroxyl radical formation, 
but alone is not sufficient to kill macrophages. 
Two mechanisms can lead to a decreased GSH/GSSG ratio: 
accumulation of GSSG or loss of GSH with insufficient conversion of GSSG into 
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GSH [96]. Under conditions of marked oxidative stress, intracellular GSSG can 
increase substantially [102]. Multiple mechanisms can contribute to this increase: 
i) non-enzymatic oxidation of GSH ii) GSH is converted to GSSG by glutathione 
peroxidase (GPx), which catalyzes the reduction of H2O2 and other peroxides. iii) 
conversion of PSSG to PSH by GRx-SH and subsequent recycling of Grx-SSG to 
Grx-SH (Figure 3). We observed an apparent decrease in GSSG level in the 
macrophages treated with OxLDL, implying that the collapse of the GSH/GSSG 
ratio in response to OxLDL might be precipitated primarily by a decrease in GSH, 
not the accumulation of GSSG. However, the experiments performed in 
DEM+BSO treated macrophages demonstrated that macrophages will maintain 
the GSH/GSSG ratio even under GSH depleted conditions as one would expect 
if GR remains fully functional. Close examination of the effect of OxLDL on GSH 
and GSSG levels reveals that in fact GSSG levels do not decrease at the same 
rate as GSH. This could either be due to loss of GR activity and/or enhanced 
GSSG formation. Further experiments are needed to determine which 
mechanism leads to the decreased ratio. 
Although the molecular mechanism involved is not clear, GSH depletion is 
likely to occur via GSH efflux or GSH conjugates including GSSG and 4-HNE-GS. 
If glutathione is transported out of the cell as GSH and GSSG, we would have 
detected a significant increase in extracellular GSHtot that correlated with the 
decrease in intracellular GSH level. However, that was not observed. Therefore, 
GSH efflux does not appear to be responsible for the depletion of GSH. OxLDL 
contains high concentration of aldehydes including 4-HNE [21, 105]. Darley-
Usmar and coworkers demonstrated that pure 4-HNE and OxLDL deplete GSH 
from monocyte-like THP-1 cells [25]. Hartley and coworkers suggested that the 
mechanism by which 4-HNE depletes the GSH involves the conjugation of GSH 
with 4-HNE to form 4-HNE-GS which is transported out of cells [109]. If GSH 
conjugates with alkenals, alkylated conjugates would probably not be reduced by 
DTT [109] because DTT only reduces reversible sulfhydryl modifications such as 
intramolecular disulfide, mixed disulfide, or sulfenate [77]. Thus, the method 
described by Paroni et al. would not detect the change in extracellular GSHtot. 
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Given the ability of GSH conjugates to lead to the depletion of GSH in OxLDL-
treated human macrophages, we reasoned that the 4-HNE may mimic the 
cytotoxicity of OxLDL in human macrophages. As predicted, 4-HNE caused 
macrophage death which was correlated with the depletion of GSH and a 
decrease in the GSH/GSSG ratio. However, Trolox did not protect against 4-
HNE-induced toxicity (data not shown), suggesting that HNE cannot be the agent 
or alkenal in OxLDL that does the killing. Together, these data indicate that the 
pathway of decreased GSH/GSSG ratio contributes to OxLDL-induced 
macrophage death. Furthermore, the decrease in the GSH/GSSG ratio is not 
caused by the reduction of cellular glutathione alone. Therefore, our data suggest 
that GSH depletion appears to contribute to OxLDL-induced cell injury and may 
result from the conjugation between GSH and OxLDL-derived alkenals. 
The shift in the ratio of GSH/GSSG changes the cellular redox state. 
Changes in the cellular redox environment can alter signal transduction, DNA 
and RNA synthesis, protein synthesis, enzyme activation, and even regulation of 
the cell cycle [34-36]. Thus, a significant decrease in the GSH/GSSG ratio may 
also lead to cell death. Changes in the intracellular redox state induced by a 
decreasing GSH/GSSG ratio or the increased formation of peroxyl radicals can 
promote the formation of mixed disulfides between protein cysteine residues and 
GSH, a process referred to as protein-S-glutathionylation [42, 77]. Protein-S-
glutathionylation alters (mostly inhibits) protein function and/or activity [85]. 
Protein-S-glutathionylation is reversible, however, once it reaches a critical level, 
macrophages are likely to become dysfunctional and die. We therefore speculate 
that the accumulation of PSSG may contribute to OxLDL-induced macrophage 
death. However, we could not detect a significant increase in PSSG in response 
to OxLDL (100 µg/ml), unless we added BCNU. One possible explanation is that 
only a small number of proteins critical for cell survival are S-glutathionylated. 
Unless these proteins would make up at least 10% of the total macrophage 
protein, we would not have detected an increase in total PSSG. Alternatively, 
cytosolic PSSG may have leaked out of the dying cells. However, in the 
presence of BCNU, OxLDL stimulated PSSG formation, which correlated also 
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with a dramatic increase in cell cytotoxicity. Inhibition of glutathione reductase 
(GR) with BCNU promotes the accumulation of GSSG. This may slow down the 
regeneration of Grx-SSG and thus decrease the rate of PSSG regeneration, 
effectively resulting in the accumulation of PSSG. These data show that OxLDL 
promotes protein-S-glutathionylation and that increased PSSG formation appears 
to play a critical role in OxLDL toxicity in human macrophages. We also observed 
that Trolox blocked PSSG formation and restored cell viability. This result 
suggests that peroxyl radical formation appears to be involved in the 
accumulation of PSSG.  
The mechanisms by which PSSG accumulated in human macrophages 
treated with OxLDL are unclear. The formation of PSSG by GSH transfer from 
GSSG to PSH would require that the intracellular GSH/GSSG ratio have to drop 
below 10-13 [110]. But in most cells and tissues, such a low GSH/GSSG ratio in 
the cytosol is rare because of the ability of many cells to export GSSG, a 
protective response against oxidative stress [111]. Indeed, when OxLDL at 75 
ug/ml killed half of macrophages, the GSH/GSSG ratio was still well above 10. 
Hence, high GSSG levels or a decrease in the GSH/GSSG ratio is not a likely 
mechanism for PSSG formation in OxLDL-induced macrophages. Alternatively, 
ROS, in particular radicals, could promote PSSG [42, 64, 77]. Indeed, treatment 
of cells with Trolox inhibited the formation of PSSG and blocked OxLDL-induced 
macrophage death, suggesting that peroxyl radicals may contribute to PSSG 
formation. It is also possible that the depletion of GSH promotes the formation of 
PSSG in OxLDL-induced macrophages. In support of this mechanism, 
Glutaredoxin (GRX) is the primary enzyme involved in the deglutathionylation of 
PSSG requiring GSH as cofactor [42, 77]. The depletion of GSH would therefore 
reduce the level of active GRx and hence prevent the deglutathionylation of 
PSSG, resulting in the accumulation of PSSG in OxLDL-induced macrophages. 
To test this hypothesis, human macrophages could be supplemented with GSH 
prior to treatment with OxLDL. GSH is taken up only in small amounts by cells 
[112]. But GSH diethyl ester transports more efficiently into cells where it is 
rapidly hydrolyzed to GSH monoethyl and then to GSH [113]. Hence, GSH 
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diethyl ester can be added in culture medium to increase GSH level. We would 
expect that the formation of PSSG and cell cytotoxicity induced by OxLDL will be 
decreased after the addition of GSH diethyl ester.   
 Accumulation of PSSG has been reported in different cell types under a 
variety of oxidative conditions [49]. GRx has been characterized in vitro as a 
specific catalyst for the reduction of PSSG [42]. When the activity of GRx was 
downregulated 70% by siRNA interference, cell toxicity induced by OxLDL was 
increased 30%, indicating that the involvement of PSSG formation in OxLDL-
induced macrophage death and an important role for GRx in protecting 
macrophages from OxLDL toxicity. 
GR can catalyze the reduction of GSSG, and in vivo, GR is also required 
for the conversion of GRx into its reduced, i.e. active state [73].  Inhibiting GR 
expression with siRNA against GR dramatically increased OxLDL-induced 
macrophage death, demonstrating that inhibition of GR activity would increase 
both GSSG accumulation and PSSG formation, and prevent the 
deglutathionylation of PSSG due to a reduction in the level of active GRx. 
Furthermore, treatment with GR inhibitor BCNU, which causes the accumulation 
of GSSG, sensitized macrophages to OxLDL toxicity, indicating the importance of 
thiol oxidation and the protective role of GR in OxLDL-induced macrophage 
death. However, it is not likely that OxLDL directly inactivates GR. This 
conclusion is based on our observation that OxLDL alone did not promote a 
detectable increase in PSSG level. But when GR activity was inhibited by BCNU, 
the PSSG level induced by OxLDL dramatically increased. 
Our data are summarized in the hypothetical model of OxLDL-induced 
human macrophage death shown in figure 12. Our model suggests that OxLDL 
contains lipid hydroperoxides (LOOH) which are most likely the precursors of 
peroxyl radicals [24]. The formation of peroxides can be blocked by peroxyl 
radical scavenger Trolox and GPx, which reduce LOOH to LOH using GSH as 
substrate. But the detoxification of peroxides via GPx produces more GSSG [114, 
115]. The study of Asmis et al. [23] suggests that the formation of peroxyl radical 
causes mitochondrial dysfucntion, thereby promoting macrophage lysis.  Here we 
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show that alterations in the thiol redox state contribute to OxLDL-induced 
macrophage death. Our data demonstrate that the depletion of GSH in 
macrophages results from the conjugation of GSH with 4-HNE or other alkenals 
presented in OxLDL particle rather than GSH efflux. However, the depletion of 
GSH alone cannot explain the decrease in the GSH/GSSG ratio because under 
normal physiological condition, GR converts GSSG to GSH faster than GSSG is 
formed, resulting in the reduced GSSG level. Hence, macrophage death is only 
observed under conditions where GSSG levels decreases to a lesser extent than 
GSH, i.e. due to either loss of GR activity and/or enhanced  
 
 
 
Figure 12: Hypothetical Model of OxLDL-induced macrophage death  
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GSSG formation, a decreased GSH/GSSG ratio can be observed. It is 
conceivable that increased GR activity can inhibit the decreased GSH/GSSG 
ratio as a result of reducing the accumulation of GSSG.  
The change in the thiol redox state and peroxyl radical formation is 
independent pathways in OxLDL toxicity and both of them are required for 
OxLDL-induced macrophage death. The depletion of glutathione or the 
decreased GSH/GSSG ratio is the fundamental defect that renders macrophages 
vulnerable to killing by the peroxyl radical formation, but alone is not sufficient to 
induce macrophage death. Furthermore, Trolox inhibits the formation of PSSG 
and cell death as result of suppression of peroxide formation. Hence, the 
formation of peroxides and/or the depletion of GSH may induce the accumulation 
of PSSG. When the increased formation of PSSG reaches a critical level, 
macrophages are likely to become dysfunctional and die.  
GRx, a catalyst of the deglutathionylation of PSSG, and GR required for 
the regeneration of GSH from GSSG and the restoration of GRx activity, play 
protective roles in OxLDL-induced macrophage death. Therefore, Grx enzyme 
system is likely to delay the progression of atherosclerotic lesions through 
reducing the death of macrophage death. The GRx and GR are important future 
targets to develop clinical therapies for atherosclerosis associated with oxidative 
stress. 
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APPENDIX 
 
ABBREVIATIONS: 
 
BCNU: 1,3-bis[2-Chloroethyl]-1-nitrosourea 
BSO: L-buthionine-sulfoximine  
DEM: Diethyl maleate 
DTT: Dithiothreitol 
γ-GCS: γ-glutamylcysteine synthetase  
GPx: Glutathione peroxidase  
GR: Glutathione reductase  
GRx: Glutaredoxin 
GS: Glutathione synthetase 
GSH: Reduced glutathione or γ-glu-cys-gly 
GST: Glutathione-s-transferase 
GSSG: Glutathione disulfide  
4-HNE: 4-Hydroxynonenal 
 IKK: IkB kinase 
LOOH: Lipid hydroperoxides   
NEM: N-ethylmaleimide  
OxLDL: Oxidatively modified LDL  
PSSG: Protein-glutathionyl-mixed disulfides  
ROS: Reactive oxygen species  
TRx: Thioredoxin  
TRxR: Thioredoxin reductase 
TDOR: Thiol-disulfide oxidoreductase  
Trolox: 6-Hydroxy-2,5,7,8-tetremethyl-chroman-2-carboxylic acid 
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